Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MRC Technology

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

- PMLiVE

AZ faces early competition to Nexium in the US

Korea's Hanmi and Amneal Pharmaceuticals launches first generic rival

german flag

BMS and AZ pull diabetes drug in Germany

Unable to agree price with health authorities

- PMLiVE

Good news for AZ on gout candidate lesinurad

Phase III trial backs planned filing in 2014

- PMLiVE

AZ donates Brixham lab to Plymouth University

Will create global research and education facility

- PMLiVE

AZ wins EU approval for four-strain flu vaccine

Fluenz Tetra offers competition to GSK’s Influsplit Tetra/Fluarix Tetra

- PMLiVE

AZ said to be eyeing Forest takeover bid

Financial Times says pharma companies are in early negotiations

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

- PMLiVE

AZ drug for opioid constipation starts FDA review

Naloxegol on course to compete with Takeda’s Amitiza

- PMLiVE

MedImmune appoints head of research

Yong-Jun Liu to lead R&D at AstraZeneca biologics subsidiary

- PMLiVE

AZ invests £120m in UK cancer drug production

New facility in Macclesfield to manufacture Zoladex will retain 300 jobs

Bristol-Myers Squibb (BMS) building

BMS exits hep C, diabetes and neuroscience drug discovery

Will discontinue 'broad-based discovery work' in the therapy areas

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links